Subscribe
Core coverageTEVA

Company profile / TEVA

Teva Pharmaceutical Industries Ltd.

Clinaptis stanceNeutral
ConvictionLow
Ticker
TEVA
Exchange
NYSE
Coverage
Standard profile
Updated
Sep 26, 2026
Specialty Pharmaceuticals / Neuroscience / Immunology / Generics

Global pharmaceutical company using its generics, biosimilars, OTC and distribution platform to fund a shift toward higher-margin innovative medicines. Current growth is led by AUSTEDO, AJOVY and UZEDY. The next launch cycle includes olanzapine LAI and ecopipam, while partnered duvakitug and internally discovered TEV-'408 are the principal biologic-development assets.

01 / Clinaptis view

The current read

Initial read: operationally constructive, valuation-disciplined. Teva has turned an opioid-, leverage- and generics-dominated recovery into a credible specialty-pharma transition.

  1. AUSTEDO, AJOVY and UZEDY generated more than $1.0 billion in 2Q26, mix is lifting gross margin, debt has fallen and Fitch, Moody's and S&P have restored investment-grade ratings. The stock has also more than doubled from $19.27 on September 24, 2025 to $40.22 on September 24, 2026, just below its September high.
  2. At approximately $47.9 billion of fully diluted equity value and $60.8 billion of enterprise value, TEVA trades near 12x normalized 2026 EBITDA after reversing the disclosed Emalex acquisition charge. The turnaround discount has therefore largely closed.
  3. Upside now requires the branded portfolio and pipeline to deliver the next earnings leg rather than merely avoiding another balance-sheet problem. AUSTEDO remains the cash-flow engine and roughly two-thirds of guided 2026 revenue from the three key brands.
  4. Olanzapine LAI is differentiated delivery rather than new biology; ecopipam was acquired after Phase 3 and used an enriched randomized-withdrawal design; duvakitug has shared major-market economics; and TEV-'408 remains early. The operating transformation is real, but the valuation now pulls forward part of the handoff before it has occurred.
02 / Consensus gap

Where the market may differ

The bullish framing treats TEVA as a still-cheap large-cap biopharma whose current earnings understate AUSTEDO durability, a new long-acting-injectable franchise and immunology optionality. The generics platform funds the transition, investment-grade credit lowers refinancing risk and existing commercial infrastructure should create operating leverage as new specialty products launch.

  1. The harder read is that the shares have already crossed from repair to execution. AUSTEDO faces a Medicare negotiated price from January 2027, U.S. generics are contracting as lenalidomide competition intensifies, several pipeline assets carry royalties or profit sharing, and $4.85 billion of recorded legal provisions remain.
  2. The nationwide opioid settlement converted the largest open-ended liability into a largely estimable payment stream, but generic-drug antitrust and price-fixing litigation remains unresolved. The central valuation question is no longer whether Teva survives its legacy liabilities.
  3. It is whether AUSTEDO volume, the 2027 margin program and the next launch cycle can justify the richer multiple while the biologics portfolio matures.
Coverage state
Standard profile
What the review turns on
Key variable

Whether AUSTEDO-led growth and the 2027 margin program can absorb Medicare pricing and generic erosion while olanzapine LAI, ecopipam and immunology begin a credible earnings handoff

Next catalyst

Olanzapine LAI (TEV-'749) · FDA decision and potential U.S. launch · Q4 2026; the final label and any post-injection monitoring requirement determine commercial value

03 / Pipeline

Key programs

9 assets · 9 programs

AssetIndicationStageNext event
AUSTEDO / AUSTEDO XR
Tardive dyskinesia and chorea associated with Huntington's disease
Commercial
Medicare negotiated price takes effect January 1, 2027; volume growth and XR mix must offset the net-price reset
AJOVY
Migraine prevention
Commercial
Quarterly volume, gross-to-net and ex-U.S. performance after milestone- and allowance-influenced 2026 growth
UZEDY
Schizophrenia and bipolar I maintenance
Commercial
Prescription growth and expansion of the long-acting-injectable commercial franchise ahead of olanzapine LAI
Olanzapine LAI (TEV-'749)
Schizophrenia
NDA under FDA review
FDA decision and potential U.S. launch in Q4 2026; label and monitoring requirements are decisive
Ecopipam (EBS-101)
Tourette syndrome in children and adolescents
NDA submitted
FDA acceptance, review classification and PDUFA timing
Duvakitug (TEV-'574)
Ulcerative colitis and Crohn's disease
Phase 3
Phase 3 execution and expansion studies in hidradenitis suppurativa and fibrostenotic Crohn's disease
TEV-'408
Vitiligo and celiac disease
Phase 2
Vitiligo Phase 2b initiation in Q4 2026 and definition of the next controlled celiac study
DARI (TEV-'248)
Asthma rescue treatment
Phase 3
Phase 3 results and regulatory-path update
Emrusolmin (TEV-'286)
Multiple system atrophy
Phase 2
Phase 2 efficacy and safety results
04 / Connected research

Published on TEVA

View full archive
No published research attached

The profile is live. The research connection is still open.

When a Clinaptis article includes TEVA in its research metadata, it will appear here automatically.

Browse all research